Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2020 Feb;25(2):e391-e395.
doi: 10.1634/theoncologist.2019-0467. Epub 2019 Nov 6.

Sicca Syndrome Induced by Immune Checkpoint Inhibitor Therapy: Optimal Management Still Pending

Ariadna Ortiz Brugués  1 , Vincent Sibaud  2 , Beatrice Herbault-Barrés  3 , Sarah Betrian  4 , Iphigenie Korakis  4 , Caroline De Bataille  5 , Carlos Gomez-Roca  4 , Joel Epstein  6 , Emmanuelle Vigarios  5
Affiliations
Comment

Sicca Syndrome Induced by Immune Checkpoint Inhibitor Therapy: Optimal Management Still Pending

Ariadna Ortiz Brugués et al. Oncologist. 2020 Feb.

Abstract

Commenting on a recently published article on sicca syndrome linked to immune checkpoint inhibitor therapy, this letter to the editor shares another viewpoint on the management of this immune‐related adverse event.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Lymphohistiocytic infiltrate surrounding salivary glands (hematoxylin and eosin staining, original magnification ×10).
Figure 2
Figure 2
Immunostaining showing CD3‐positive T‐cell infiltrate (original magnification ×10) (A), CD4‐positive T‐cell infiltrate (original magnification ×10) (B) and CD8‐positive T‐cell infiltrate (original magnification ×10) (C).
Figure 3
Figure 3
Grade 3 xerostomia induced by anti‐programmed death‐ligand 1.
See this image and copyright information in PMC

Comment in

  • In Reply.
    Warner B, Baer A. Warner B, et al. Oncologist. 2020 Feb;25(2):e396-e397. doi: 10.1634/theoncologist.2019-0515. Epub 2019 Nov 6. Oncologist. 2020. PMID: 32043773 Free PMC article.

Comment on

  • Sicca Syndrome Associated with Immune Checkpoint Inhibitor Therapy.
    Warner BM, Baer AN, Lipson EJ, Allen C, Hinrichs C, Rajan A, Pelayo E, Beach M, Gulley JL, Madan RA, Feliciano J, Grisius M, Long L, Powers A, Kleiner DE, Cappelli L, Alevizos I. Warner BM, et al. Oncologist. 2019 Sep;24(9):1259-1269. doi: 10.1634/theoncologist.2018-0823. Epub 2019 Apr 17. Oncologist. 2019. PMID: 30996010 Free PMC article.

References

    1. Warner BM, Baer AN, Lipson EJ et al. Sicca syndrome associated with immune checkpoint inhibitor therapy. The Oncologist 2019;24:1259–1269. - PMC - PubMed
    1. Shiboski CH, Shiboski SC, Seror R et al. 2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjögren's syndrome: A consensus and data‐driven methodology involving three international patient cohorts. Ann Rheum Dis 2017;76:9–16. - PubMed
    1. Le Burel S, Champiat S, Routier E et al. Onset of connective tissue disease following anti‐PD1/PD‐L1 cancer immunotherapy. Ann Rheum Dis 2018;77:468–470. - PubMed
    1. Ghosn J, Vicino A, Michielin O et al. A severe case of neuro‐Sjögren's syndrome induced by pembrolizumab. J Immunother Cancer 2018;6:110. - PMC - PubMed
    1. Vigarios E, Epstein JB, Sibaud V. Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors. Support Care Cancer 2017;25:1713–1739. - PubMed